Depo Medroxyprogesterone acetate

Phase 3Small molecule

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Depo Medroxyprogesterone acetate is one of 72 small molecule programs targeting Contraception. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ContraceptionActive, not recruiting

EndometriosisActive, not recruiting

ContraceptionPreclinical

Active, not recruiting

EndometriosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

199 competitors in Endometriosis

#DrugCompanyPhaseTrials

Revia

Teva

Phase 3

1 2

Leuprorelin

Takeda

Phase 3

8 3

Orgovyx

Sumitomo Pharma America, Inc.

Phase 3

3 4

Firmagon

Ferring

Phase 3

1 5

Estradiol/norethindrone Acetate

AbbVie

Phase 3

5 6

Esketamine Hydrochloride

TThe Second Hospital of Anhui Medical University

Phase 3

1 7

EE20/DRSP(BAY86-5300)

Bayer

Phase 3

1 8

Indole-3-Carbinol

UUniversity of Kansas Medical Center

Phase 3

1 9

Add-Back

KKissei Pharmaceutical Co., Ltd.

Phase 3

4 10

Visanne

Bayer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Contraception3 trials

Hormonal Contraception and Risk of Chlamydia and Gonorrhea

Terminated·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)··NCT00091728·1,200 enrolled

Clinical Trial on the Effects of Progestin-based Contraception in the Genital Tract of HIV-infected and Uninfected Women

Completed·CCenters for Disease Control and Prevention·Phase 4·NCT02103660·131 enrolled

Investigating the Interaction Between Two Long-acting Reversible Methods of Contraception and Dolutegravir, a Treatment for HIV

Unknown status·BBotswana Harvard AIDS Institute Partnership·Phase 4·NCT04910711·140 enrolled

Pilot Study1 trial

Measuring Lactation Initiation After Early Postpartum Injectable Progestin (DMPA) Use Among Women in Dhanusha District of Nepal: A Pilot Study

Completed·UUniversity of California, San Diego·Phase 4·NCT06816901·40 enrolled

Interaction1 trial

Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT01296152·25 enrolled

Progesterone1 trial

Randomized Control Trial Copper Intrauterine Device and Depo-medroxyprogesterone Acetate (DMPA) of HIV+ Women in Malawi

Completed·EEmory University·N/A·NCT01191203·200 enrolled

Endometriosis1 trial

Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery

Completed·UUniversitas Diponegoro·Phase 3·NCT06145438·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Depo Medroxyprogesterone acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Depo Medroxyprogesterone acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Depo Medroxyprogesterone acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Depo Medroxyprogesterone acetate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Contraception3 trials

Pilot Study1 trial

Interaction1 trial

Progesterone1 trial

Endometriosis1 trial

References

Drug Info

Quick Facts

Related News